Hoeltig Doris, Rohde Judith, Brunner Birgit, Hellmann Klaus, Grandemange Erik, Waldmann Karl-Heinz
1Clinic for Swine, Small Ruminants, forensic Medicine and Ambulatory Service, University of Veterinary Medicine Hannover, Foundation, Bischofsholer Damm 15, D-30173 Hannover, Germany.
2Institute for Microbiology, University of Veterinary Medicine Hannover, Foundation, Bischofsholer Damm 15, D-30173 Hannover, Germany.
Porcine Health Manag. 2018 Jun 22;4:13. doi: 10.1186/s40813-018-0089-2. eCollection 2018.
Porcine pleuropneumonia, caused by is a bacterial respiratory disease of swine. Acute outbreaks of the disease are often accompanied by high mortality and economic losses. As severe cases of the disease frequently require parenteral antibiotic treatment of the animals, the efficacy of a single, high dose of marbofloxacin was compared to a three-time application of a dose of enrofloxacin under experimental conditions.
A blinded, controlled, randomized and blocked dose confirmation study was conducted to test the efficacy and safety of a single dose of 8 mg/kg marbofloxacin (160 mg/ml, Forcyl® Swine, Vetoquinol SA, France) to treat acute porcine pleuropneumonia after experimental aerosol inoculation of pigs with serotype 2. The results were compared to a three consecutive day treatment of 2.5 mg/kg enrofloxacin and a mock (saline) treatment. Criteria for the assessment of efficacy were severity of lung lesions, bacteriological cure and the course of clinical disease after treatment.
Thirty six nursery pigs were divided into three treatment groups: marbofloxacin (T1), enrofloxacin (T2) and mock (T3). Statistically significant superiority ( < 0.05) of marbofloxacin and enrofloxacin compared to the mock-treated group was demonstrated for all efficacy criteria. The need of rescue euthanasia due to severity of symptoms was significantly reduced in both treatment groups (T1: 1 pig; T2: 0 pigs; vs. T3: 8 pigs). On day 6 after treatment initiation, clinical cure was observed in 10 (T1), 10 (T2) but only 1 of the piglets in T3. Extent of lung lesions (mean of lung lesion score T1: 3.9, T2: 6.0, T3: 21.1) and bacteriological isolation from lung tissue (on day 6 after treatment initiation: T1 = 0 pigs; T2 = 1 pig; T3 = all pigs) were also significantly reduced within both treatment groups. There were no adverse events linked to the drug administration and no injection site reactions were observed.
Both applied antimicrobial treatments were proven safe and efficacious for the treatment of acute porcine pleuropneumonia. No statistically significant differences were detected between the antibiotic treatments.
由[病原体名称缺失]引起的猪胸膜肺炎是猪的一种细菌性呼吸道疾病。该病的急性暴发通常伴随着高死亡率和经济损失。由于该病的严重病例常常需要对动物进行肠胃外抗生素治疗，因此在实验条件下比较了单次高剂量的马波沙星与三次应用恩诺沙星的疗效。
进行了一项双盲、对照、随机和分组剂量确认研究，以测试单次8毫克/千克马波沙星（160毫克/毫升，Forcyl® Swine，法国威隆公司）治疗猪经实验性气溶胶接种2型[病原体名称缺失]后的急性猪胸膜肺炎的疗效和安全性。将结果与连续三天给予2.5毫克/千克恩诺沙星的治疗以及模拟（生理盐水）治疗进行比较。疗效评估标准为肺部病变的严重程度、细菌学治愈情况以及治疗后的临床病程。
三十六头保育猪被分为三个治疗组：马波沙星组（T1）、恩诺沙星组（T2）和模拟组（T3）。对于所有疗效标准，马波沙星组和恩诺沙星组与模拟治疗组相比均显示出统计学上的显著优势（P < 0.05）。两个治疗组因症状严重程度而需要实施安乐死的情况均显著减少（T1：1头猪；T2：0头猪；T3：8头猪）。在开始治疗后的第6天，T1组有10头猪、T2组有10头猪实现临床治愈，而T3组只有1头仔猪临床治愈。肺部病变程度（肺部病变评分平均值：T1组为3.9，T2组为6.0，T3组为21.1）以及从肺组织中进行细菌分离的情况（在开始治疗后的第6天：T1组 = 0头猪；T2组 = 1头猪；T3组 = 所有猪）在两个治疗组中也均显著降低。未观察到与药物给药相关的不良事件，也未观察到注射部位反应。
两种应用的抗菌治疗方法均被证明对治疗急性猪胸膜肺炎安全有效。在抗生素治疗之间未检测到统计学上的显著差异。
